- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05184374
Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH
December 22, 2021 updated by: Zhaoyun Zhang, Huashan Hospital
Efficacy of Prolonged Gonadorelin Stimulation Test in Male Adolescents With Postoperative Hypogonadotropic Hypogonadism
The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy.
The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient.
Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis.
GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH.
After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment.
GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cuiyun Wu
- Phone Number: +86(21)52888045
- Email: mhe2004@263.net
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Recruiting
- Huashan Hospital
-
Contact:
- Cuiyun Wu
- Phone Number: +86(21)52888045
- Email: mhe2004@263.net
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- patients with HH after surgery of the saddle area
- sufficient therapy of the hypothalamic-pituitary-adrenal(HPA) and hypothalamic-pituitary-thyroid(HPT) axis
Exclusion Criteria:
- contradictions to gonadorelin
- androgen-dependent prostate cancer
- on the therapy of human chorionic gonadotropin(HCG) or testosterone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: subcutaneous injection of gonadorelin is facilitated by GnRH pump
After non-dose GnRH stimulation test on day 1, GnRH pump pulse subcutaneous injection of gonadorelin on the next day until one month.
|
GnRH pump pulse subcutaneous injection of gonadorelin in a month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of luteinizing hormone, follicle stimulating hormone and testosterone
Time Frame: 1 month
|
after the GnRH pump of gonadorelin, the level of luteinizing hormone, follicle stimulating hormone and testosterone will be measured at 24h, 1, 2, 3 and 4 week
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2022
Primary Completion (Anticipated)
June 30, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
December 22, 2021
First Submitted That Met QC Criteria
December 22, 2021
First Posted (Actual)
January 11, 2022
Study Record Updates
Last Update Posted (Actual)
January 11, 2022
Last Update Submitted That Met QC Criteria
December 22, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2021-674
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadotropic Hypogonadism
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Fudan UniversityRecruitingIdiopathic Hypogonadotropic Hypogonadism | Luteal Phase Support | Luteal Phase DeficiencyChina
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingAcquired Hypogonadotropic HypogonadismItaly
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalTerminatedHypothalamic Amenorrhea | Idiopathic Hypogonadotropic HypogonadismUnited States
-
Ferring PharmaceuticalsCompletedPrimary Amenorrhea With Hypogonadotropic HypogonadismUnited States, Canada
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Stephanie B. Seminara, MDRecruitingHypogonadotropic HypogonadismUnited States
Clinical Trials on Gonadorelin
-
Ferring PharmaceuticalsCompletedPrimary Amenorrhea With Hypogonadotropic HypogonadismUnited States, Canada
-
Hospital de Niños R. Gutierrez de Buenos AiresCompletedCentral Precocious Puberty | Sexual PrecocityArgentina
-
Peking Union Medical College HospitalUnknownHypogonadotropic HypogonadismChina
-
National Institute on Drug Abuse (NIDA)Mclean HospitalCompleted
-
Nelly PitteloudRecruitingDown Syndrome | Cognitive Decline | Alzheimer Disease, Early Onset | Olfaction DisordersSwitzerland
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedObesity | FertilityUnited States
-
RenJi HospitalUnknownPolycystic Ovary Syndrome | Infertility | Ovulation DisorderChina
-
University of Colorado, DenverCompleted
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of Colorado, DenverNational Center for Advancing Translational Sciences (NCATS)CompletedObesity | Infertility | Hyperinsulinemia | Hypogonadotropic HypogonadotropismUnited States